{"entity":{"id":"nct07769502","kind":"trial","name":"A Study to Assess Adverse Events and Change in Disease Activity With Treatment Combinations With Telisotuzumab Adizutecan in Adults Participants With Pancreatob","aka":[],"tldr":"A phase 2 trial of telisotuzumab adizutecan, gemcitabine and nab-paclitaxel in pancreatic cancer, run by AbbVie, now recruiting.","summary":"A Study to Assess Adverse Events and Change in Disease Activity With Treatment Combinations With Telisotuzumab Adizutecan in Adults Participants With Pancreatobiliary Cancers is a phase 2, randomised interventional study registered as NCT07769502 by AbbVie, with a registry enrolment figure of 168 participants, started 2026-08-17 and due to reach its primary completion in 2028-09. Interventions recorded: Telisotuzumab Adizutecan; Gemcitabine; Nab-Paclitaxel. Conditions listed: Pancreatobiliary Cancers; Pancreatic Ductal Adenocarcinoma. Primary outcome: Overall Response (OR) Assessed by Blinded Independent Central Review (BICR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1; Number of Participants with Adverse Events (AEs). Sites: Israel, Japan, Taiwan. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07769502","url":"https://clinicaltrials.gov/study/NCT07769502"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":["cytotoxic-chemotherapy"],"targets":[],"drugs":["telisotuzumab-adizutecan","gemcitabine","nab-paclitaxel"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07769502","phase":"2","setting":"A Phase 2, Open-Label, Master Protocol Study to Evaluate Safety and Efficacy of Treatment Combinations With Telisotuzumab Adizutecan in Subjects With Pancreatobiliary Cancers (AndroMETa-118)","sponsor":"AbbVie","enrolled":168,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07769502/","neighbours":{"cancer":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"}],"drug":[{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/"},{"id":"nab-paclitaxel","kind":"drug","name":"Nab-paclitaxel","route":"/drugs/nab-paclitaxel/"},{"id":"telisotuzumab-adizutecan","kind":"drug","name":"Telisotuzumab adizutecan","route":"/drugs/telisotuzumab-adizutecan/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}